Drug Name

Classification

Dosage

Action

Indications

Contraindications

Drug Interaction

Side Effects

Nursing Considerations

Generic Name: Keterolac

Brand Name: Toradol

Nonsteroidal AntiInflammatory Drugs (NSAIDs) / Oph thalmic Decongestants, Anesthetics, AntiInflammatories

Adult: PO Mode rate to severe pain 10 mg 4-6 hrly. Max: 40 mg/day. Max duration: 7 days. IV/IM Mo derate to severe pain 60 mg via IM inj or 30 mg via IV inj. Ophth Ocul ar itching As 0.5% soln: Instill 1 drop 4 times/day. Post -op eye inflammation A s 0.5% soln: Instill 1 drop 4 times/day for 2 wk, starting 24 hr after surgery for 2 wk. Cystoid macular oedem a As 0.5% soln: Instill 1-2 drops 6-8 hrly starting 24 hr before surgery, continue for 34 wk after surgery. Pain and photophobi a after incisional refractive surgery As 0.5% soln: Instill 1 drop 4

Ketorolac reduces the production of prostaglandins , chemicals that cells of the immune system make that cause the redness,fever, and pain of inflammation and that also are believed to be important in the production of noninflammatory pain. It does this by blocking the enzymes that cells use to make prostaglandins (cyclooxygena se 1 and 2). As a result, pain as well as inflammation and its signs and symptoms - redness, swelling, fever, and pain - are reduced.

Carefully consider the potential benefits and risks of TORADOL and other treatment options before deciding to use TORADOL. Use the lowest effective dose for the shortest duration consistent with individual patient treatment goals

Hypersensitivity to aspirin or other NSAIDs, asthma. Hypovolaemia or dehydration. Do not give postoperatively to patients with high risk of haemorrhage. History of peptic ulcer or coagulation disorders. Nasal polyps, angioedema, bronchospasm. Labour. Moderate to severe renal impairment. GI bleeding, cerebrovascular bleeding. As prophylactic analgesic before surgery. Pregnancy, lactation.

May reduce effects of antihypertensives (e.g. ACE inhibitors or angiotensin II receptor antagonists). Increased risk of renal toxicity with ACE inhibitors, diuretics. Increased adverse effects with aspirin or other NSAIDs. Hallucinations may occur when used with fluoxetine, thiothixene, alprazolam. Potentially Fatal: Increased risk of GI bleeding with warfarin. May increase toxicity of methotrexate and lit hium. Increased plasma concentrations with probenecid.

GI ulcer, bleeding and perforation, drowsiness, rash, bronchospasm, hypotension, psychosis, dry mouth, fever, bradycardia, chest pain, dizziness, headache, sweating, oedema, pallor, liver function changes. Transient stinging and local irritation (ophthalmic). Potentially Fatal: Anaphylaxis. Severe skin reactions. MI, stroke, GI bleeding.

Elderly, patients weighing <50 kg, hepatic dysfunction, heart failure, predisposition to reduced blood volume or renal blood flow. Mild renal impairment; monitor renal function closely.